Evidence map›Paper›PMID 37365619›Full record

ArticleOrphanet journal of rare diseases2023

Real-world evidence in achondroplasia: considerations for a standardized data set.

Yasemin Alanay, Klaus Mohnike, Ola Nilsson, Inês Alves, Moeenaldeen AlSayed, Natasha M Appelman-Dijkstra, Genevieve Baujat, Tawfeg Ben-Omran, Sandra Breyer, Valerie Cormier-Daire and 15 more

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Yasemin AlanayPediatric Genetics, Department of Pediatrics, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Kayisdagi Cad. No:32, Atasehir, 34684, Istanbul, Turkey. yasemin.alanay@acibadem.edu.tr.ORCID 0000-0003-0683-9731
Klaus MohnikeDepartment of Pediatrics, Otto-von-Guericke-University, Magdeburg, Germany.
Ola NilssonDivision of Pediatric Endocrinology and Center for Molecular Medicine, Department of Women's and Children's Health, Karolinska Institute and University Hospital, Stockholm, Sweden.
Inês AlvesANDO Portugal, Évora, Portugal.
Moeenaldeen AlSayedDepartment of Medical Genomics, Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Natasha M Appelman-DijkstraDepartment of Internal Medicine, Division Endocrinology and Center for Bone Quality, Leiden University Medical Center, Leiden, The Netherlands.
Genevieve BaujatHôpital Necker Enfants Malades AP-HP, Paris, France.
Tawfeg Ben-OmranGenetic and Genomic Medicine Division, Sidra Medicine and Hamad Medical Corporation, Doha, Qatar.
Sandra BreyerDepartment of Paediatrics, UKE Hamburg-Eppendorf, Hamburg, Germany.
Valerie Cormier-DaireHôpital Necker Enfants Malades AP-HP, Paris, France.
Pernille Axél GregersenDepartment of Clinical Genetics and Centre for Rare Diseases, Aarhus University Hospital, Aarhus, Denmark.
Encarna Guillén-NavarroMedical Genetics Section, Department of Paediatrics, Virgen de la Arrixaca University Clinical Hospital, IMIB-Arrixaca, Faculty of Medicine, University of Murcia (UMU), Murcia, Spain.
Wolfgang HöglerDepartment of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria.
Mohamad MaghnieDepartment of Paediatrics, IRCCS Istituto Giannna Gaslini, Genoa, Italy.
Swati MukherjeeBioMarin (UK) Limited, London, UK.
Shelda CohenBioMarin (UK) Limited, London, UK.
Jeanne PimentaBioMarin (UK) Limited, London, UK.
Angelo SelicorniPediatric Unit ASST Lariana, Mariani Center for Fragile Child, Como, Italy.
J Oliver SemlerFaculty of Medicine, University of Cologne, Cologne, Germany.
Sabine SigaudyDépartement de Génétique Médicale, Hôpital Timone Enfant, Marseille, France.
Dmitry PopkovNational Ilizarov Research Center for Traumatology and Orthopaedics, Kurgan, Russia.
Ian SabirBioMarin (UK) Limited, London, UK.
Susana NovalFundación ALPE Acondroplasia, Asturias, Spain.
Marco SessaAssociazione per I'Informazione e lo Studio dell'Acondroplasia (AISAC), Milan, Italy.
Melita IrvingGuy's and St. Thomas' NHS Foundation Trust, Evelina Children's Hospital, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCollection of real-world evidence (RWE) is important in achondroplasia. Development of a prospective, shared, international resource that follows the principles of findability, accessibility, interoperability, and reuse of digital assets, and that captures long-term, high-quality data, would improve understanding of the natural history of achondroplasia, quality of life, and related outcomes.

methodsThe Europe, Middle East, and Africa (EMEA) Achondroplasia Steering Committee comprises a multidisciplinary team of 17 clinical experts and 3 advocacy organization representatives. The committee undertook an exercise to identify essential data elements for a standardized prospective registry to study the natural history of achondroplasia and related outcomes.

resultsA range of RWE on achondroplasia is being collected at EMEA centres. Whereas commonalities exist, the data elements, methods used to collect and store them, and frequency of collection vary. The topics considered most important for collection were auxological measures, sleep studies, quality of life, and neurological manifestations. Data considered essential for a prospective registry were grouped into six categories: demographics; diagnosis and patient measurements; medical issues; investigations and surgical events; medications; and outcomes possibly associated with achondroplasia treatments.

conclusionsLong-term, high-quality data are needed for this rare, multifaceted condition. Establishing registries that collect predefined data elements across age spans will provide contemporaneous prospective and longitudinal information and will be useful to improve clinical decision-making and management. It should be feasible to collect a minimum dataset with the flexibility to include country-specific criteria and pool data across countries to examine clinical outcomes associated with achondroplasia and different therapeutic approaches.

Indexed as

AchondroplasiaQuality of LifeEuropeHumansRegistriesAchondroplasiaGrowthQuality of lifeRare diseaseReal-world dataReal-world evidenceRegistry

Identifiers

PMID37365619
PMCPMC10294372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.